focus -WSS

focus

author：comprehensive 2025-09-07 14:09:25 - browse：86368

Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC. — Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： How AI can help patients find reliable information about doctors

WSS

Testing for cancer recurrence creates a new limbo for patients

The FDA weighs the risks of candy

STAT Readout: Friday, Oct. 20 biotech updates

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Smaller biotechs seek to piggyback on weight loss drug boom

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Wikipedia

focus

hotspot

At least 13 dead in Texas as scorching temps continue

Roche drug slashes death risk in early

Psychedelics group wrestles with new pharma identity

Traditional Chinese medicine benefits explored in new JAMA study

Medicare proposal to cover medical devices draws a mixed reaction

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Moonlake's readout produced a cash windfall. Risks remain

Readout LOUD podcast: Live from the 2023 STAT Summit

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

entertainment

Testing for cancer recurrence creates a new limbo for patients

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Study on Amgen’s bispecific immunotherapy produces positive data

STAT Summit: The economic case for universal basic health care

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

focus

explore

hotspot

focus